

Կլինիկական փորձարկման երաշխավորված դեղեր (2024 թ)

List of the Clinical Studies approved in 2024

Лекарственные препараты, одобренные для проведения клинических исследований в 2024

N	Name, Dosage	Manufacturer	Country	Date of approval
1.	Balstilimab 50 mg/ml Botenlimab 50 mg/ml	Vetter Pharma-Fertigung GmbH & Co	Germany	01.2024
2.	Oral Decitabine 35 mg and Cedazuridine 100 mg ASTX727-17, ASTX727-18, ASTX727-06	Astex Pharmaceuticals, Inc	USA	01.2024
3.	Telmisartan + Amlodipine Telmisartan 40 mg + Amlodipine 5 mg; Telmisartan 80 mg + Amlodipine 5 mg; Telmisartan 80 mg + Amlodipine 10 mg;	KRKA	Slovenia	02.2024
4.	Telmisartan + Amlodipine Hydrochlorothiazide Telmisartan 80 mg + Amlodipine 5 mg+12,5mg Hydrochlorothiazide; Telmisartan 80 mg + Amlodipine 10 mg+12,5mg Hydrochlorothiazide; Telmisartan 80 mg + Amlodipine 10 mg+25mg Hydrochlorothiazide	KRKA	Slovenia	02.2024
5.	Naldemedine Naldemedine 0.2 mg tablets; Naldemedine 0.2 mg/g powder for oral suspension	Shionogi B.V. Almac Clinical Services Limited	UK	05.2024
6.	Beclometasone dipropionate 200 mcg + Formoterol fumarate 6 mcg + Glycopyrronium bromide 12.5 mcg with hydrofluoroalkaline (HFA)-152a propellant via pMDI.	CHIESI FARMACEUTICI S.P.A.	Italy	05.2024
7.	Floxadex 3 mg/ml + 1 mg/ml, eye/ear drops, suspension	Liquor	RA	05.2024
8.	Ivosidenib 250 mg tablet	Institut de Recherches	France	05.2024

		Internationales Servier		
9.	Gliclazide MR 60 mg tablet	Institut de Recherches Internationales Servier	France	05.2024
10.	Tamsulosin hydrochloride 0.4mg, prolonged-release tablet	Synthon Hispania SL	Spain	12.2024
11.	TX-000045 150mg/ml solution for infusion, 1ml in 2ml amber glass vial	Tectonic Therapeutics	China	12.2024
12.	OCTA - C1-INH C1 Esterase Inhibitor (plasma-derived, human) lyophilized powder (500 IU per vial)	Octapharma Pharmazeutika Produktionsges	Austria	12.2024
13.	Istaroxime 10mg, lyophilized powder for solution for infusion	Zhaoke Pharmaceutical (Hefei) Co. Ltd	China	12.2024